ADC Therapeutics Announces Medical Leadership Transition
September 03 2021 - 7:15AM
Business Wire
ADC Therapeutics SA (NYSE: ADCT), a commercial-stage
biotechnology company improving the lives of those affected by
cancer with its next-generation, targeted antibody drug conjugates
(ADCs) for patients with hematologic malignancies and solid tumors,
announced today that Jay Feingold, MD, PhD, Senior Vice President
and Chief Medical Officer, will depart the company to pursue a new
opportunity. ADCT is pleased to announce that Joseph Camardo, MD,
will be appointed Senior Vice President and Chief Medical
Officer.
“Jay Feingold has played a key role in the growth of ADC
Therapeutics over the last seven years and was instrumental in
establishing our clinical team and strategy leading to the approval
of our first commercial therapy, ZYNLONTA®,” said Chris Martin,
PhD, Chief Executive Officer. “We are grateful for his leadership,
expertise and steadfast dedication to patients, and we wish him
well in his next endeavor.” Dr. Feingold will continue to consult
with ADCT through 2022 to ensure a smooth transition.
Dr. Camardo joined ADC Therapeutics from Celgene Corporation,
where he was most recently Senior Vice President of Celgene Global
Health after having served as Senior Vice President of Global
Medical Affairs and Corporate Medical Operations. Prior to Celgene,
Dr. Camardo was Senior Vice President of Clinical Development and
Medical Affairs at Forest Research Institute and spent more than 20
years at Wyeth Research before its acquisition by Pfizer. At Wyeth,
he held several leadership roles including Senior Vice President of
Clinical Research and Development.
“Dr. Camardo’s extensive background in clinical development and
Medical Affairs makes him the ideal successor and ensures a
seamless evolution of our company. Dr. Camardo worked closely with
Dr. Feingold for the last 18 months and together they ensured our
first marketed product was well-received by the physician community
in the United States and beyond,” continued Chris Martin.
“On behalf of the Board of Directors, I am delighted to welcome
Dr. Camardo to the pivotal role of Chief Medical Officer,” said Ron
Squarer, Chairman of the Board and an advisor to the company. “The
Board has worked closely with Joe Camardo on several critical
projects and appreciates his vast and deep industry experience, as
well as his passion for patients.”
About ADC Therapeutics
ADC Therapeutics (NYSE: ADCT) is a commercial-stage
biotechnology company improving the lives of those affected by
cancer with its next-generation, targeted antibody drug conjugates
(ADCs). The Company is advancing its proprietary PBD-based ADC
technology to transform the treatment paradigm for patients with
hematologic malignancies and solid tumors.
ADC Therapeutics’ CD19-directed ADC ZYNLONTA (loncastuximab
tesirine-lpyl) is approved by the FDA for the treatment of relapsed
or refractory diffuse large b-cell lymphoma after two or more lines
of systemic therapy. ZYNLONTA is also in development in combination
with other agents. Cami (camidanlumab tesirine) is being evaluated
in a late-stage clinical trial for relapsed or refractory Hodgkin
lymphoma and in a Phase 1b clinical trial for various advanced
solid tumors. In addition to ZYNLONTA and Cami, ADC Therapeutics
has multiple PBD-based ADCs in ongoing clinical and preclinical
development.
ADC Therapeutics is based in Lausanne (Biopôle), Switzerland and
has operations in London, the San Francisco Bay Area and New
Jersey. For more information, please visit
https://adctherapeutics.com/ and follow the Company on Twitter and
LinkedIn.
ZYNLONTA® is a registered trademark of ADC Therapeutics SA.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210903005046/en/
Investors Eugenia Litz ADC Therapeutics
Eugenia.Litz@adctherapeutics.com +44 7879 627205
Amanda Hamilton ADC Therapeutics
amanda.hamilton@adctherapeutics.com +1 917-288-7023 USA Media Mary
Ann Ondish ADC Therapeutics maryann.ondish@adctherapeutics.com
Tel.: +1 914-552-4625 EU Media Alexandre Müller Dynamics Group
amu@dynamicsgroup.ch +41 (0) 43 268 3231
ADC Therapeutics (NYSE:ADCT)
Historical Stock Chart
From Mar 2024 to Apr 2024
ADC Therapeutics (NYSE:ADCT)
Historical Stock Chart
From Apr 2023 to Apr 2024